7 results
Summary of dosing recommendations in renal impairment of commonly used hypoglycaemic agents

#Diabetes #Diabetic #Medications #Pharmacology #Dosing
Summary of dosing ... hypoglycaemic agents #Diabetes ... #Diabetic #Medications ... #Pharmacology # ... Renal #Impairment #CKD
Management of Diabetes Mellitus in Patients With CKD

1. Monitor for changes in BP, serum creatinine, &
Management of Diabetes ... or Type 2 diabetes ... #Diabetes #CKD # ... ADA #KDIGO #eGFR ... #Insulin #metformin
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... Insulin Lifestyle ... modifications Metformin ... EricsMedicalLectures/featured #diabetes
Metformin in Diabetic Kidney Disease
Immediate release:
 • Initial 500 mg or 850 mg once daily
 •
Metformin in Diabetic ... maximum dose eGFR ... recommended dose eGFR ... < 30: Stop metformin ... #CKD #pharmacology
Metformin Pharmacology Summary
Mechanisms of Action:
 • Suppresses gluconeogenesis by the liver
 • Increases insulin-mediated glucose utilization
Metformin Pharmacology ... Summary Mechanisms ... • Increases insulin-mediated ... #Pharmacology # ... Summary #DM2 #diabetes
Estimating the Total Daily Dose (TDD) of Insulin: Weight-Based Dosing
TDD in units of insulin = N
(stage IV or V CKD ... including most type 1 diabetics ... including most 2 diabetics ... Weight #Based #pharmacology ... endocrinology #diabetes
Sulfonylureas - Pharmacology Summary
Mechanisms of Action: Binds to the ATP-sensitive potassium channel in pancreatic beta cells,
Sulfonylureas - Pharmacology ... Summary Mechanisms ... cells, triggering insulin ... contraindicated in CKD ... diabetes #endocrinology